FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3047935875> ?p ?o ?g. }

• W3047935875 endingPage "105126" @default.
• W3047935875 startingPage "105126" @default.
• W3047935875 abstract "With the global epidemic of coronavirus disease (COVID-19), China has made progress in the prevention and control of the epidemic, and traditional Chinese medicine (TCM) has played a key role in dealing with the disease’s effects on the respiratory system. This randomized controlled clinical trial evaluated the clinical efficacy and prognosis of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in patients with COVID-19. A total of 283 patients participated in this clinical trial, and participants were randomly assigned to receive either 1) Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules or 2) Linahua granules, both combined with western medicine, or 3) western medicine alone for 14 days. At the end of the trial, the improvement and resolution rates of clinical symptoms and the rate of patients who progressed to severe disease status were evaluated. After 14 days of treatment, there was no significant difference in the improvement rate of clinical symptoms among the three groups (P > 0.05). Huoxiang Zhengqi dropping pills combined with Lianhua Qingwen granules has advantages in the treatment of nausea, vomiting and limb soreness. During treatment, all participants were treated with western medicine, and there was a significant difference in the use of macrolides among the three groups (P < 0.05). Specifically, the utilization rate of antibiotics in the western medicine group was significantly greater than that of the other two groups. Among the 182 diagnosed patients who completed this clinical trial, 13 patients progressed to severe disease, including one case in the Huoxiang + Lianhua group (1.6 %), five cases in the Lianhua group (8.6 %), and seven cases in the western medicine group (11.1 %). There was no statistical differences in this rate among the three groups (P > 0.05). However, the proportion of patients who progressed to severe disease in the Huoxiang + Lianhua group was the lowest, suggesting that the combination of TCM with western medicine has a potential advantage in improving the prognosis of patients with COVID-19. The use of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules combined with western medicine may have clinical advantages for COVID-19 patients in improving clinical symptoms, reducing utilization rate of anti-infective drugs, and improving patient prognosis, which could pave the way for the use of complementary medicine in treating this infection." @default.
• W3047935875 created "2020-08-13" @default.
• W3047935875 creator A5003181280 @default.
• W3047935875 creator A5004033178 @default.
• W3047935875 creator A5004704117 @default.
• W3047935875 creator A5004987000 @default.
• W3047935875 creator A5009090854 @default.
• W3047935875 creator A5014432190 @default.
• W3047935875 creator A5014841945 @default.
• W3047935875 creator A5015572160 @default.
• W3047935875 creator A5021437777 @default.
• W3047935875 creator A5021459831 @default.
• W3047935875 creator A5028439973 @default.
• W3047935875 creator A5030997396 @default.
• W3047935875 creator A5038611998 @default.
• W3047935875 creator A5038881186 @default.
• W3047935875 creator A5040925154 @default.
• W3047935875 creator A5042973046 @default.
• W3047935875 creator A5044902751 @default.
• W3047935875 creator A5045754045 @default.
• W3047935875 creator A5046300933 @default.
• W3047935875 creator A5049640172 @default.
• W3047935875 creator A5051491443 @default.
• W3047935875 creator A5058047717 @default.
• W3047935875 creator A5060107207 @default.
• W3047935875 creator A5060692095 @default.
• W3047935875 creator A5074818476 @default.
• W3047935875 creator A5081984770 @default.
• W3047935875 creator A5082588749 @default.
• W3047935875 creator A5088141818 @default.
• W3047935875 date "2020-11-01" @default.
• W3047935875 modified "2023-10-17" @default.
• W3047935875 title "Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial" @default.
• W3047935875 cites W2010581642 @default.
• W3047935875 cites W2053959512 @default.
• W3047935875 cites W2368021181 @default.
• W3047935875 cites W2395008877 @default.
• W3047935875 cites W2418096135 @default.
• W3047935875 cites W2591486315 @default.
• W3047935875 cites W3006394629 @default.
• W3047935875 cites W3009906937 @default.
• W3047935875 cites W3011090040 @default.
• W3047935875 cites W3013180764 @default.
• W3047935875 doi "https://doi.org/10.1016/j.phrs.2020.105126" @default.
• W3047935875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7414728" @default.
• W3047935875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32781283" @default.
• W3047935875 hasPublicationYear "2020" @default.
• W3047935875 type Work @default.
• W3047935875 sameAs 3047935875 @default.
• W3047935875 citedByCount "137" @default.
• W3047935875 countsByYear W30479358752020 @default.
• W3047935875 countsByYear W30479358752021 @default.
• W3047935875 countsByYear W30479358752022 @default.
• W3047935875 countsByYear W30479358752023 @default.
• W3047935875 crossrefType "journal-article" @default.
• W3047935875 hasAuthorship W3047935875A5003181280 @default.
• W3047935875 hasAuthorship W3047935875A5004033178 @default.
• W3047935875 hasAuthorship W3047935875A5004704117 @default.
• W3047935875 hasAuthorship W3047935875A5004987000 @default.
• W3047935875 hasAuthorship W3047935875A5009090854 @default.
• W3047935875 hasAuthorship W3047935875A5014432190 @default.
• W3047935875 hasAuthorship W3047935875A5014841945 @default.
• W3047935875 hasAuthorship W3047935875A5015572160 @default.
• W3047935875 hasAuthorship W3047935875A5021437777 @default.
• W3047935875 hasAuthorship W3047935875A5021459831 @default.
• W3047935875 hasAuthorship W3047935875A5028439973 @default.
• W3047935875 hasAuthorship W3047935875A5030997396 @default.
• W3047935875 hasAuthorship W3047935875A5038611998 @default.
• W3047935875 hasAuthorship W3047935875A5038881186 @default.
• W3047935875 hasAuthorship W3047935875A5040925154 @default.
• W3047935875 hasAuthorship W3047935875A5042973046 @default.
• W3047935875 hasAuthorship W3047935875A5044902751 @default.
• W3047935875 hasAuthorship W3047935875A5045754045 @default.
• W3047935875 hasAuthorship W3047935875A5046300933 @default.
• W3047935875 hasAuthorship W3047935875A5049640172 @default.
• W3047935875 hasAuthorship W3047935875A5051491443 @default.
• W3047935875 hasAuthorship W3047935875A5058047717 @default.
• W3047935875 hasAuthorship W3047935875A5060107207 @default.
• W3047935875 hasAuthorship W3047935875A5060692095 @default.
• W3047935875 hasAuthorship W3047935875A5074818476 @default.
• W3047935875 hasAuthorship W3047935875A5081984770 @default.
• W3047935875 hasAuthorship W3047935875A5082588749 @default.
• W3047935875 hasAuthorship W3047935875A5088141818 @default.
• W3047935875 hasBestOaLocation W30479358751 @default.
• W3047935875 hasConcept C126322002 @default.
• W3047935875 hasConcept C142724271 @default.
• W3047935875 hasConcept C168563851 @default.
• W3047935875 hasConcept C188947578 @default.
• W3047935875 hasConcept C204787440 @default.
• W3047935875 hasConcept C2779134260 @default.
• W3047935875 hasConcept C2780580376 @default.
• W3047935875 hasConcept C3008058167 @default.
• W3047935875 hasConcept C524204448 @default.
• W3047935875 hasConcept C535046627 @default.
• W3047935875 hasConcept C556039675 @default.
• W3047935875 hasConcept C71924100 @default.
• W3047935875 hasConcept C81603835 @default.
• W3047935875 hasConcept C98274493 @default.

• next